# Contact Tesamorelin Source: Editorial Correspondence About the Research

> Contact Tesamorelin Source about the published tesamorelin research summarized on this site. Editorial correspondence only — we are not a clinic and provide no medical advice or product.

For corrections, citation questions, or editorial feedback on the tesamorelin literature summarized here.

## Editorial correspondence

Tesamorelin Source welcomes correspondence about the tesamorelin research summarized on this site — corrections to a citation, a study we should add, or feedback on how a finding is framed. We read every message about the literature, and a well-sourced correction is the most useful thing you can send us.

We cannot answer requests for medical advice, dosing guidance, prescriptions, or product. We are an editorial publisher, not a clinic or a vendor: we do not employ clinicians, we do not provide treatment, and we do not sell, supply, or dispense tesamorelin or any other compound. Questions of that kind belong with a qualified healthcare professional who can weigh your individual circumstances.

## What to include

If you are flagging a citation issue, the most useful messages name the page, quote the sentence, and point to the study or identifier (PubMed ID or DOI) you have in mind. If you are suggesting a study, a link to the PubMed record is ideal — peer-reviewed primary research, systematic reviews, and authoritative monographs are what this site is built from. Use the form fields below to send a name, an email address, a subject, and your message; there is no account to create and nothing to buy.

We read correspondence about the literature and update pages when a correction is warranted. We do not respond to requests to source, price, or supply tesamorelin, because we do none of those things. For the questions we are asked most often, the [common questions about tesamorelin](/faq) page may already have an answer.

---

Tesamorelin read down to its numbers — one GHRH(1-44) analogue, the visceral-fat and IGF-1 figures left standing alone against the studies that measured them, and the approved-for-HIV-lipodystrophy line drawn exactly where the off-label field begins; an editorial reference plate, not a clinic, a vendor, or a prescription.